Immunome (NASDAQ:IMNM) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on shares of Immunome (NASDAQ:IMNM) in a research report report published on Tuesday, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $24.00 price objective on the stock.

A number of other equities research analysts also recently issued reports on the stock. Leerink Partnrs reissued an outperform rating on shares of Immunome in a research report on Monday, January 29th. Guggenheim assumed coverage on shares of Immunome in a report on Monday, April 15th. They issued a buy rating and a $35.00 target price for the company. Wedbush upped their target price on shares of Immunome from $27.00 to $33.00 and gave the stock an outperform rating in a report on Monday, April 1st. Finally, SVB Leerink initiated coverage on shares of Immunome in a report on Monday, January 29th. They issued an outperform rating and a $30.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $30.50.

Immunome Trading Up 1.7 %

NASDAQ:IMNM opened at $14.06 on Tuesday. Immunome has a 12 month low of $4.44 and a 12 month high of $30.96. The company has a 50 day simple moving average of $21.76 and a two-hundred day simple moving average of $15.24. The company has a market cap of $839.24 million, a PE ratio of -2.61 and a beta of 1.66.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, March 28th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.26). Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. The business had revenue of $3.83 million for the quarter, compared to the consensus estimate of $3.40 million. Research analysts forecast that Immunome will post -1.91 earnings per share for the current year.

Institutional Trading of Immunome

Hedge funds have recently made changes to their positions in the business. Avidity Partners Management LP purchased a new stake in Immunome in the 4th quarter worth about $14,268,000. TD Asset Management Inc purchased a new stake in Immunome in the 3rd quarter worth about $1,063,000. Mayo Clinic purchased a new stake in Immunome in the 4th quarter worth about $1,161,000. Cerity Partners LLC purchased a new stake in Immunome in the 4th quarter worth about $656,000. Finally, Emfo LLC purchased a new stake in Immunome in the 4th quarter worth about $633,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.